Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells

Histone deacetylase inhibitors (HDACIs) can disrupt the viability of prostate cancer (PCa) cells through modulation of the cytosolic androgen receptor (AR) chaperone protein heat shock protein 90 (HSP90). However, toxicities associated with their pleiotropic effects could contribute to the ineffecti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Pharmacol
Hlavní autoři: Rosati, Rayna, Chen, Bailing, Patki, Mugdha, McFall, Thomas, Ou, Siyu, Heath, Elisabeth, Ratnam, Manohar, Qin, Zhihui
Médium: Artigo
Jazyk:Inglês
Vydáno: The American Society for Pharmacology and Experimental Therapeutics 2016
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4998664/
https://ncbi.nlm.nih.gov/pubmed/27382012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.116.103416
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky